Actionable news
0
All posts from Actionable news
Actionable news in DEPO: Depomed, Inc.,

Prospectuses and communications, business combinations

BGCOLOR="WHITE">

Filed pursuant to Rule 425

of the Securities Act of 1933, as amended,

and deemed filed pursuant to Rule 14a-12

of the Securities Exchange Act of 1934, as amended

Filing by: Horizon Pharma public l imited company

Subject Company: Depomed, Inc.

SEC File No. of Depomed, Inc.: 001-13111

This Rule 425 filing consists of a press release which contains information regarding the proposed acquisition of Depomed, Inc. by Horizon Pharma plc (Horizon Pharma).

Horizon Pharma plc Files Definitive Proxy Statement for Extraordinary

General Meeting of Horizon Pharma Shareholders

Principal Purpose of the Meeting is To Take Actions

Relating to Horizon Pharmas Proposed Acquisition of Depomed, Inc.

DUBLIN, IRELAND October 15, 2015 Horizon Pharma plc (NASDAQ: HZNP) (Horizon Pharma), a biopharmaceutical company focused on improving patients lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it has filed a definitive proxy statement on Schedule 14A with the Securities and Exchange Commission (SEC) in connection with the extraordinary general meeting of Horizon Pharma shareholders (the Meeting). The principal purpose of the Meeting is to approve the issuance of Horizon ordinary shares in connection with Horizon Pharmas proposed acquisition of Depomed, Inc.

The Extraordinary General Meeting of Horizon Pharma shareholders is currently scheduled for 4:00 p.m., local time, on Friday, November 13, 2015 at Horizon Pharmas corporate headquarters Connaught House, 1 st Floor, 1 Burlington Road, Dublin 4, D04 C5Y6, Ireland.

At the Meeting, Horizon Pharma shareholders will also be asked to approve an increase in the authorized share capital of Horizon Pharma and related proposals to give the Horizon Pharma board an updated authority under Irish law to allot and issue Horizon Pharma ordinary shares and an updated power under Irish law to issue Horizon Pharma ordinary shares for cash without first offering those shares to existing shareholders. Approval by shareholders of these additional share capital proposals, as described in the proxy statement, is not required to complete an acquisition of Depomed, Inc. (including on a negotiated basis). Shareholders will also be asked to approve any motion to adjourn the Meeting, or any adjournments thereof, to another time and place if necessary or appropriate.

In connection with the offer and the second-step merger with Depomed, Inc. that Horizon Pharma has currently proposed, Horizon Pharma has also filed with the SEC, amendment 2 to its registration statement on Form S-4, as previously amended on September 25, 2015.

About Horizon Pharma plc

Horizon Pharma plc is a biopharmaceutical company focused on improving patients lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets seven medicines through its orphan, primary care and specialty business units. Horizon Pharmas global headquarters are in Dublin, Ireland. For more...


More